The vision ofthe Charles Drew University of Medicine and Science (CDU) Research Enterprise is to be a leading national resource for conducting clinical and translational research that produces high-quality, costeffective and culturally relevant solutions that improve health and wellness in minority and poor populations. By promoting strategies that create synergy in research teams and between investigators and the community, CDU will create novel best practice solutions to transform the health of underserved communities that can be used as innovative models throughout the nation and the world. CDU submits this application in response to the NIH Program Announcement (PAR-08-262) to implement the consolidation of the Comprehensive Center for Health Disparities (CCHD) and Clinical Research Center (CRC) into Accelerating excellence In Science (AXIS). AXIS will be the catalyst to implement the CDU research strategic plan and will become the integrated """"""""home"""""""" for clinical and translational research. AXIS will house experienced and dedicated leadership;a myriad of clinical and translational, community, training, and technology resources;and excellent research consultation services. As its cornerstone, AXIS wi|l have multiand interdisciplinary collaborations between CDU investigators and community partners. These team science activities will be supported by CDU biomedical informatics resources, and other innovative research tools and information technologies (detailed below) aligned in an integrated manner to create a vibrant center for clinical and translational science. The overall purpose of AXIS is to better position CDU for conducting clinical and translational research, especially research that is focused on health disparities. The goals are to: Goal 1: Transform the CDU research enterprise from traditional basic and clinical research domains into a highly integrated clinical and translational research environment by reorganizing research administration, centralizing and enhancing physical and intellectual resources, and promoting participation in the RCMI Translational Research Network (RTRN) and Clinical and Translational Science Institutes (CTSI). Goal 2: Develop a unique model for community, multi-disciplinary, and/or multi-institutional partnerships that ensures that clinical and translational research yields high-quality, cost-effective health outcomes Goal 3: Implement innovative translational research training and career development activities at CDU and in partnership with RTRN that recognize that the interdependence of basic science, clinical discovery, and patient-oriented research will accelerate improved patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54MD007598-05
Application #
8514420
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Program Officer
Mcclure, Shelia A
Project Start
2009-09-28
Project End
2014-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2013
Total Cost
$3,773,195
Indirect Cost
$1,091,204
Name
Charles R. Drew University of Medicine & Science
Department
Type
Other Domestic Higher Education
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Jenders, Robert A; Adlassnig, Klaus-Peter; Fehre, Karsten et al. (2018) Evolution of the Arden Syntax: Key Technical Issues from the Standards Development Organization Perspective. Artif Intell Med 92:10-14
Maxwell, Annette E; Castillo, Laura; Arce, Anthony A et al. (2018) Eating Veggies Is Fun! An Implementation Pilot Study in Partnership With a YMCA in South Los Angeles. Prev Chronic Dis 15:E132
Elshimali, Yahya I; Wu, Yong; Khaddour, Hussein et al. (2018) Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 1:
Hanuscin, Chris; Zahmatkesh, Golara; Shirazi, Anaheed et al. (2018) Socio-Demographic and Mental Health Profile of Admitted Cases of Self-Inflicted Harm in the US Population. Int J Environ Res Public Health 15:
Hasan, Mohammad Kamrul; Friedman, Theodore C; Sims, Carl et al. (2018) ?7-Nicotinic Acetylcholine Receptor Agonist Ameliorates Nicotine Plus High-Fat Diet-Induced Hepatic Steatosis in Male Mice by Inhibiting Oxidative Stress and Stimulating AMPK Signaling. Endocrinology 159:931-944
Elsaid, Ahmed F; Shaheen, Magda; Ghoneum, Mamdooh (2018) Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial. Exp Ther Med 15:2313-2320
Sinha-Hikim, Amiya P; Mahata, Sushil K (2018) Editorial: Obesity, Smoking, and Fatty Liver Disease. Front Endocrinol (Lausanne) 9:1
Chung, Seyung S; Dutta, Pranabananda; Austin, David et al. (2018) Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget 9:32943-32957
Schwartz, Steven; Bazargan-Hejazi, Shahrzad; Pan, Deyu et al. (2018) Association of Psychiatric Diagnostic Conditions with Hospital Care Outcomes of Patients with Orthopedic Injuries. Perm J 22:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:

Showing the most recent 10 out of 190 publications